BARDA and Immunexpress Inc. expand partnership to evaluate a sepsis host-based laboratory diagnostic to triage COVID-19 patients
Biomedical Advanced Research and Development Authority (BARDA) announced a collaboration with Seattle’s Immunexpress Inc. to determine the risk of sepsis in hospitalized COVID-19 patients.